FARMACIA HOSPITALARIA最新文献

{"title":"[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice","authors":"Maria Choví-Trull ,&nbsp;Juan Eduardo Megías-Vericat ,&nbsp;Santiago Bonanad Boix ,&nbsp;Saturnino Haya Guaita ,&nbsp;Ana Rosa Cid Haro ,&nbsp;Marta Aguilar Rodriguez ,&nbsp;Jose Luis Poveda Andrés","doi":"10.1016/j.farma.2024.12.007","DOIUrl":"10.1016/j.farma.2024.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>To analyse the differences in pharmacokinetic and clinical parameters (bleeding rates and joint health) before and after switching from standard half-life factor VIII (FVIII) to extended half-life pegylated FVIII in patients with severe/moderate haemophilia A on prophylaxis, 1 year before and after the switch in real-life.</div></div><div><h3>Method</h3><div>This is a single-centre, comparative, observational, sequential, retrospective, and multidisciplinary study. Population pharmacokinetic models from the WAPPS-Hemo® application were used to calculate pharmacokinetic parameters and individualise prophylaxis. The annual rate of total and joint bleeds, joint health (Haemophilia Joint Health Score), plasma half-life and area under the curve ratios, FVIII consumption, administration frequency, and cost were analysed.</div></div><div><h3>Results</h3><div>Thirty-eight adult patients with haemophilia A who switched from standard half-life FVIII to extended half-life pegylated FVIII were analysed. Significant improvements (<em>P</em> &lt; .05) were observed in all pharmacokinetic parameters, with plasma half-life and area under the curve improvement ratios of 1.5 and 1.9, respectively, as well as reductions in annual total and joint bleeding rates. A higher number of patients with zero total (16.0 vs. 29.0) and joint bleeds (23.0 vs. 33.0) was also observed. The median reductions in administration frequency and dose/kg/week were 30.0% and 19.7%, respectively, avoiding 44.3 infusions/patient/year, resulting in savings of 20,843 €/patient/year. Furthermore, joint health improved (23.0 vs. 21.0; <em>P</em> = .017), and target joints resolved after the switch.</div></div><div><h3>Conclusions</h3><div>The pharmacokinetically guided switch from standard half-life FVIII to pegylated FVIII demonstrated significant clinical benefits with reduced bleeding rates and improvements in joint health. Additionally, improvements in pharmacokinetic parameters were observed, allowing for reduced treatment burden by decreasing administration frequency, as well as lower consumption and costs.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T205-T211"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] The need for prolonged antiviral use to prevent recurrences of herpes simplex virus ocular disease: A systematic review","authors":"Laura Ruiz Sifre ,&nbsp;Sylvia Bort Martí ,&nbsp;Vicente Ruiz García ,&nbsp;Ángeles Ruth Bort Martí","doi":"10.1016/j.farma.2025.03.019","DOIUrl":"10.1016/j.farma.2025.03.019","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate in patients with a history of keratitis by herpes simplex virus, ocular recurrences, visual acuity, non-ocular recurrences, stromal keratitis and adverse effects after prolonged treatment with antiviral agents. Registered in Prospero CRD42024556228.</div></div><div><h3>Methods</h3><div>Systematic review of trials identified in CENTRAL, Embase, Medline, <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<span><span>www.who.int/ictrp</span><svg><path></path></svg></span>). Trials of patients with a history of at least one episode of herpes simplex keratitis were included. Participants had to be free of active herpetic disease at the time of enrollment in the trial. Trials had to include oral and/or topical antiviral agents versus placebo or other antivirals, administered for at least 4 weeks. A data extraction was performed by pairs with risk of bias assessment for each trial using Cochrane Risk of Bias; GRADE was used to provide the certainty of evidence for each outcome.</div></div><div><h3>Results</h3><div>Four trials were found that included 1,017 patients. Antivirals in prolonged use protected from recurrences of ocular herpetic disease better than placebo (RR 0.56; 95% CI 0.45–0.70) NNT 6 (4–11); acyclovir was better than placebo in this same action (RR 0.59; 95% CI 0.46–0.74) NNT 8 (5–14), but not different from valacyclovir (RR 1.0; 95% CI 0.37–2.70) NNT not calculated. Prolonged use of antivirals also decreased recurrences of non-ocular herpetic disease (RR 0.56; 95% CI 0.44–0.71) NNT 6 (5–11) and recurrences with stromal keratitis (RR 0.55; 95% CI 0.35–0.85) NNT 17 (10–50). No data were found on visual acuity. Regarding adverse effects, there were no differences between interventions (RR 0.96; 95% CI 0.60–1.54) NNT not calculated. The certainty of evidence was high for ocular and non-ocular recurrences, and low for adverse effects, due to imprecision and inconsistency of the findings.</div></div><div><h3>Conclusions</h3><div>Prolonged use of antivirals protects from ocular, non-ocular recurrences and stromal keratitis safely. The effects on visual acuity are not known.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T235-T242"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Persistencia real a largo plazo de secukinumab en pacientes con psoriasis moderada a grave","authors":"Joaquín Borrás-Blasco ,&nbsp;Silvia Cornejo ,&nbsp;Alejandro Valcuende-Rosique ,&nbsp;Rebeca Alcalá ,&nbsp;Ana Navalón Bono","doi":"10.1016/j.farma.2025.02.001","DOIUrl":"10.1016/j.farma.2025.02.001","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.</div></div><div><h3>Methods</h3><div>Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnóstico, weight, prior failed treatments, duration of treatment and psoriasis area severity index score (PASI). Adherence was measured using medication possession ratio (MPR); patients with MPR more than 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan–Meier analysis was used to estimate secukinumab persistence using 1-year intervals.</div></div><div><h3>Results</h3><div>A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). Thirty-four (38.6%) patients discontinued secukinumab treatment due to the following reasons. Nineteen (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± 21.7 months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 61.5 ± 12.4 months followed by 54.1 ± 14.8 months for naïve patients (<em>p</em> = 0.804). Secukinumab persistence at 1 year, 2 years and 3 years was 72.7, 51.1 and 39.8%, respectively.</div></div><div><h3>Conclusions</h3><div>Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T200-T204"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Impact of pharmaceutical care on adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia","authors":"Betel Del Rosario García ,&nbsp;María Micaela Viña Romero ,&nbsp;Virginia González Rosa ,&nbsp;Carolina Alarcón Payer ,&nbsp;Leonor Oliva Oliva ,&nbsp;Gloria Julia Nazco Casariego ,&nbsp;Fernando Gutiérrez Nicolás","doi":"10.1016/j.farma.2025.03.018","DOIUrl":"10.1016/j.farma.2025.03.018","url":null,"abstract":"<div><h3>Aims</h3><div>Tyrosine kinase inhibitors (TKIs) have been successful in changing the course of chronic myeloid leukaemia (CML) due to their high efficacy. However, their effectiveness is conditioned by adherence to treatment. The aim of this study was to analyse the adherence of CML patients treated with TKIs and to evaluate the impact of pharmaceutical care on adherence in a prospective and interventional manner.</div></div><div><h3>Methods</h3><div>Multicentre, prospective study including CML patients on treatment with TKIs attending the outpatient units of the Pharmacy Services. Adherence was assessed using a combination of two methods: the Simplified Adherence Problems Scale and the treatment dispensing register (a patient with a percentage &lt;<!--> <!-->90% being considered “<em>non-adherent</em>”); patients who demonstrated a non-adherence in either of these two methods were classified as “<em>non-adherent patients</em>”. In individuals with inadequate adherence, pharmaceutical care was reinforced for 8 months by means of a specific programme.</div></div><div><h3>Results</h3><div>A total of 130 patients were included, 56.9% had optimal adherence to treatment. Pharmaceutical care in the oncohaematology-specific outpatient units of the Pharmacy Services improved adherence (from 67.1% to 90.9%; <em>p</em> &lt; 0.001) while the generalist outpatient units kept it constant (from 70.2% to 72.4%; <em>p =</em> 0.509).</div></div><div><h3>Conclusions</h3><div>Adherence is one of the most relevant parameters in the effectiveness of chronic treatments. Approximately half of our CML patients showed inadequate adherence to TKIs. This is the first prospective study to determine that the pharmacist's actions in oncohaematology-specific outpatient units of the Pharmacy Services are capable of influencing adherence and improving it.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T212-T217"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspectos éticos de la inteligencia artificial (IA) en farmacia hospitalaria","authors":"José Manuel Martínez Sesmero","doi":"10.1016/j.farma.2025.05.001","DOIUrl":"10.1016/j.farma.2025.05.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 198-199"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto de la atención farmacéutica en la adherencia a los inhibidores de la tirosin-cinasa en la leucemia mieloide crónica","authors":"Betel Del Rosario García ,&nbsp;María Micaela Viña Romero ,&nbsp;Virginia González Rosa ,&nbsp;Carolina Alarcón Payer ,&nbsp;Leonor Oliva Oliva ,&nbsp;Gloria Julia Nazco Casariego ,&nbsp;Fernando Gutiérrez Nicolás","doi":"10.1016/j.farma.2024.11.009","DOIUrl":"10.1016/j.farma.2024.11.009","url":null,"abstract":"<div><h3>Aims</h3><div>Tyrosine kinase inhibitors (TKIs) have been successful in changing the course of chronic myeloid leukaemia (CML) due to their high efficacy. However, their effectiveness is conditioned by adherence to treatment. The aim of this study was to analyse the adherence of CML patients treated with TKIs and to evaluate the impact of pharmaceutical care on adherence in a prospective and interventional manner.</div></div><div><h3>Methods</h3><div>Multicentre, prospective study including CML patients on treatment with TKIs attending the outpatient units of the Pharmacy Services. Adherence was assessed using a combination of two methods: the Simplified Adherence Problems Scale and the treatment dispensing register (a patient with a percentage &lt;<!--> <!-->90% being considered “<em>non-adherent</em>”); patients who demonstrated a non-adherence in either of these two methods were classified as “<em>non-adherent patients</em>”. In individuals with inadequate adherence, PC was reinforced for 8 months by means of a specific programme.</div></div><div><h3>Results</h3><div>A total of 130 patients were included, 56.9% had optimal adherence to treatment. Pharmaceutical care in the oncohaematology-specific outpatient units of the Pharmacy Services improved adherence (from 67.1% to 90.9%; <em>p</em> &lt; 0.001) while the generalist outpatient units kept it constant (from 70.2% to 72.4%; <em>p =</em> 0.509).</div></div><div><h3>Conclusions</h3><div>Adherence is one of the most relevant parameters in the effectiveness of chronic treatments. Approximately half of our CML patients showed inadequate adherence to TKIs. This is the first prospective study to determine that the pharmacist's actions in oncohaematology-specific outpatient units of the Pharmacy Services are capable of influencing adherence and improving it.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 212-217"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicamentos de alto riesgo: programa multidisciplinar para mejorar la seguridad del paciente hospitalizado","authors":"Maria Dolores Canales-Siguero ,&nbsp;Jose Manuel Caro-Teller ,&nbsp;Siria Pablos-Bravo ,&nbsp;Pedro Pablo Rodríguez-Quesada ,&nbsp;Delicias Quintana-Estelles ,&nbsp;Pilar Gomis-Muñoz ,&nbsp;Angel Tejido-Sanchéz ,&nbsp;Jose Miguel Ferrari-Piquero","doi":"10.1016/j.farma.2025.03.009","DOIUrl":"10.1016/j.farma.2025.03.009","url":null,"abstract":"<div><h3>Introduction</h3><div>High-risk medications (HRMs) are those with a high probability of causing severe or fatal harm when errors occur during their use. Enhancing safety in the management of HRMs is a priority for healthcare authorities. This study presents a multidisciplinary program designed to optimize the safe use of HRMs in adult inpatients at a Level 5 hospital.</div></div><div><h3>Objectives</h3><div>The objectives of the program are: a) To adapt national and international standards on HRM safety to the local setting. b) To define the competencies and responsibilities of the professionals involved. c) To increase the engagement of stakeholders in HRM safety. d) To establish indicators to evaluate the interventions.</div></div><div><h3>Methods</h3><div>The program was developed in three phases: 1) Initial situation analysis: Assessment using the Institute for Safe Medication Practices’ self-assessment questionnaire on medication safety. 2) Protocol development: Creation of a local protocol based on a literature review and multidisciplinary consensus. 3) Action plan implementation: Dissemination, monitoring, and periodic updates of the protocol.</div></div><div><h3>Results</h3><div>The developed protocol included seven general measures, 29 specific measures, and five indicators to evaluate its impact. After the first year of implementation: 71.5% of HRMs were stored in high-security locations within automated dispensing systems, 71.36% of HRM prescriptions were validated within the first 24 hours and a total of 4,366 pharmaceutical interventions were performed.</div><div>Additional measures implemented included: Tall Man Lettering across all information systems, automated alerts for maximum doses in prescribing systems and alerts prompting independent double-checking during HRM dispensing.</div></div><div><h3>Conclusions</h3><div>This program is an effective and transferable model for improving HRM safety in complex hospital settings and fostering a safety culture. Future initiatives should focus on developing a national dashboard with standardized indicators to enable inter-hospital comparisons and identify areas for improvement.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 225-229"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] OrPhar-SEFH 2024–2027 Strategic Plan","authors":"Mónica Climente Martí ,&nbsp;María Dolores Edo Solsona ,&nbsp;María Reyes Abad Sazatornil ,&nbsp;María Pilar Bachiller Cacho ,&nbsp;Sergio Fernández Espinola ,&nbsp;Paula Guijarro Martínez ,&nbsp;Elena Gras Colomer ,&nbsp;Alicia Herrero Ambrosio ,&nbsp;Silvia Manrique Rodríguez ,&nbsp;Isabel Martín Herranz ,&nbsp;José Manuel Martínez Sesmero ,&nbsp;José Luis Poveda Andrés","doi":"10.1016/j.farma.2025.05.004","DOIUrl":"10.1016/j.farma.2025.05.004","url":null,"abstract":"<div><div>To promote the transformation of hospital pharmacy in the field of rare diseases, the OrPhar-SEFH Strategic Plan 2024–2027 was developed. Twelve hospital pharmacists from the OrPhar-SEFH group participated in the project which was developed in 3 phases: Situation analysis, trends, and current challenges in rare diseases and their impact on the role of hospital pharmacist through literature review, interviews with hospital pharmacists and patients (FundAME and Fedhemo), and SWOT analysis; Definition of lines of action grouped into five strategic axes AEIOU (Alliances, Evidence, Research/Innovation, Optimization, and Union); and Prioritization of lines of action based on impact and feasibility. In order to achieve this, the existing trends and barriers in the field of rare diseases and hospital pharmacy were identified and classified around 4 levers for change: transformation of the care process, patient experience, evaluation and access to orphan drugs, and real-world evidence. The SWOT analysis identified key success factors, and interviews with patients identified their needs in four pillars: role of the hospital pharmacist, patient experience, patient education, and access to treatment. A total of 23 lines of action were agreed upon: Alliances (6), Evidence (3), Research/Innovation (4), Optimization (7), and Union (3). Based on their impact and feasibility, the following were prioritized: promoting hospital pharmacist collaboration in decision-making structures regarding the evaluation and positioning of orphan drugs, enhancing the role of hospital pharmacist in the critical analysis of scientific evidence in rare diseases and its translation to interdisciplinary clinical teams, encouraging the use of Multi-Criteria Decision Analysis methodology in orphan drugs, promoting the integration of hospital pharmacist into interdisciplinary teams managing patients with rare diseases, and creating a network of specialized hospital pharmacist services in rare diseases. Ultimately, the OrPhar-SEFH Strategic Plan 2024–2027 defines the roadmap to enhance the role of hospital pharmacist in addressing rare diseases, improving access and evaluation of orphan drugs, and optimizing the care process to improve health outcomes, quality of life, and patient experience.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages T243-T251"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual trajectories of polypharmacy and medication regimen complexity index in people living with HIV in Spain","authors":"Enrique Contreras Macías ,&nbsp;María de las Aguas Robustillo Cortés ,&nbsp;Ramón Morillo Verdugo","doi":"10.1016/j.farma.2024.09.009","DOIUrl":"10.1016/j.farma.2024.09.009","url":null,"abstract":"<div><h3>Background</h3><div>Polypharmacy, using 6 or more medications, may increase the risk of high medication regimen complexity index (MRCI). We aimed to identify the interrelationship between trajectories of polypharmacy and MRCI.</div></div><div><h3>Methods</h3><div>People living with HIV (PLWH) (aged ≥<!--> <!-->18) were included in from 2010 to 2021. Group-based trajectory modeling (GBTM) was used to identify polypharmacy trajectories and the complexity index of the medication regimen and the dual GBTM to identify their interrelationship.</div></div><div><h3>Results</h3><div>In total, 789 participants who met the eligibility criteria were included in the study, with a median age of 47 years. GBTM analysis was used to reveal latent polypharmacy trajectories among PLWH. The findings disclosed four distinctive trajectories, with the majority (50.8%) of the PLWH falling into the ‘low increasing’ trajectory. Furthermore, GBTM identified 2 trajectories characterized by high MRCI, and a substantial proportion (80.2%) was assigned to the ‘slightly increasing low’ trajectory group. The study revealed that younger age (&lt;<!--> <!-->50 years) was a significant predictor of membership in the ‘consistently low’ trajectory, while male gender was associated with the groups of ‘low increasing’ and ‘moderately decreasing’ polypharmacy trajectory.</div></div><div><h3>Conclusions</h3><div>GBTM failed to discern a discernible interrelationship between polypharmacy and the high MRCI. It is imperative to undertake future studies within this research domain, considering potential effect modifiers, notably the specific type of concomitant drug. This approach is crucial due to the outcomes induced by both polypharmacy and the magnitude of the pharmacotherapeutic complexity in PLWH.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 218-224"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síndrome de abstinencia por consumo de té de semillas de adormidera: caso clínico","authors":"Teresa Rovira Medina ,&nbsp;Pablo Yanes Sánchez ,&nbsp;Miriam Bullich Ramon ,&nbsp;Maria Oliver Cervelló ,&nbsp;Mònica Gómez-Valent","doi":"10.1016/j.farma.2024.11.003","DOIUrl":"10.1016/j.farma.2024.11.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 4","pages":"Pages 261-263"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}